#Canada #Montreal #Thryv Therapeutics #SGK1 inhibitors #Long QT Syndrome

Thryv Therapeutics to Present Key Research at the 2025 ESC Congress

Thryv Therapeutics Inc., a prominent clinical-stage biotech company based in Montreal, has recently announced that Dr. Saumya Das will present significant new preclinical data on the company’s lead compound, THRV-1268, at the European Society of Cardiology (ESC) Congress 2025. This pivotal event is scheduled to take place from August 29 to September 1 in Madrid, Spain.

The data presented will be crucial, not only for Thryv but also for the wider medical community, as it pertains to serious cardiac conditions such as Long QT Syndrome (LQTS), heart failure, and atrial fibrillation, all of which currently present urgent unmet medical needs. In conjunction with Thryv's presentation, research from the European Joint Programme on Rare Diseases (EJPRD) will also be showcased, emphasizing the progress in understanding SGK1’s role in cardiac pathologies.

Focus on THRV-1268

THRV-1268 is distinguished as a highly selective SGK1 (serum and glucocorticoid-regulated kinase 1) inhibitor, which has the potential to significantly alter the treatment landscape for LQTS and related heart conditions. A key angle of the research involves demonstrating the effectiveness of SGK1 inhibition in preclinical models of LQTS, particularly its influence on sodium current and action potential duration, which are critical in managing heart rhythm disorders.

Thryv's presentation will highlight the findings from a Transaortic Constriction (TAC) preclinical model that assesses both THRV-1268 and Jardiance® (empagliflozin) – an SGLT2 inhibitor currently employed in heart failure treatments. The results indicate a robust case for SGK1 inhibition, signaling a breakthrough in understanding cardiovascular inflammatory processes and fibrosis-driven remodeling, significant contributors to heart disease.

Presentation Details

Title: THRV-1268, a novel and potent SGK1 inhibitor, improved adverse cardiac remodeling beyond empagliflozin, an SGLT2 inhibitor, by reducing inflammation and fibrosis mechanisms in heart failure
Presenter: Saumya Das, MD, PhD, Co-Director, Resynchronization and Advanced Cardiac Therapeutics Program, Massachusetts General Hospital
Date: Saturday, August 30, 2025
Time: 1:15 PM - 2:00 PM CET
Location: Station 4 (Research Gateway)
Format: Moderated e-Poster
Session Link: SGLT2 Inhibitors in Heart Failure Prevention and Treatment – ESC365

In addition, another presentation will delve into SGK1’s effects on action potentials and anti-arrhythmic properties in specific LQT3 and LQT2 preclinical models. This presentation, led by Simona Casini from the Amsterdam University Medical Centre, also exemplifies the collaborative efforts in researching the therapeutic potentials of SGK1 inhibition.

About Thryv Therapeutics

Thryv Therapeutics Inc. is at the forefront of innovation in cardiac medication development. By harnessing the power of precision medicine through potent SGK1 inhibitors, Thryv aims to tackle diseases that include Long QT Syndrome, heart failure, and atrial fibrillation. The company’s commitment to understanding the mechanisms that drive these serious conditions is grounded in their scientific expertise and dedication to addressing critical healthcare needs. For further information about Thryv Therapeutics, visit www.thryvtrx.com.

In summary, Thryv Therapeutics is poised to make significant contributions to cardiac research at the 2025 ESC, with findings that could redefine approaches to treating serious heart conditions and improve patient outcomes worldwide.